ClinicalTrials.gg
RecruitingNCT07844317Updated Sep 28, 2026

Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy

An observational study in Diabetic Retinopathy (DR), sponsored by Digital Diagnostics, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Digital Diagnostics, Inc. · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
15th of 70
800 · median 161
Started
2026
with 18 others
Observational
70 of 267
8 open now
Primary completion
2027-05
later than 24 of 53 live
Registered
265th of 267
by date
Lead sponsor
4 of 267
Digital Diagnostics, Inc.

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 15th largest by planned enrollment of the 70 observational ones that give a count, is one of 19 that started in 2026, is one of 70 observational ones, reaches primary completion later than 24 of the 53 other live ones, and was the 265th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

Assessment of an autonomous AI system for diabetic retinopathy detection in adults with diabetes using retinal imaging.

03

Conditions studied

  • Diabetic Retinopathy (DR)

Browse trials for

Keywords

  • AI-enabled
  • Diabetic Retinopathy
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Diabetic adult population with no previous diagnosis of DR

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 22 years of age or older
  • Diagnosis of DM
  • Ability to understand and willing to sign a written ICF

Exclusion criteria

Exclusion Criteria:

Participants may be excluded if they have significant ocular conditions or prior ocular treatments that could interfere with retinal imaging or study assessments; are currently participating in another interventional ophthalmic clinical trial; have medical conditions that may affect study participation or data interpretation; are pregnant; or have to study-related imaging procedures.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single arm, non-randomized cohort

    Adult, 22 years or older with a diagnosis of diabetes

    Device: SaMD intended for the detection of diabetic retinopathy in adults with diabetes. · Device: An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.

Interventions

  • DeviceSaMD intended for the detection of diabetic retinopathy in adults with diabetes.

    No significant difference to other SaMDs for the detection of DR that are commercialized.

  • DeviceAn AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.

    SaMD to detect diabetic retinopathy

    Also known as: AI/ML, SaMD

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety and efficacy of an AI-based SaMD with a fundus camera for the detection of Diabetic Retinopathy

    Time frame: 1-year

07

Study locations

1 of 1 sites recruiting
  • Rovia Site Network
    Jacksonville, Florida 32216, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2027, 9 months after the start.

Of 90 observational studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 61. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 28, 2026
StartActual
Aug 24, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844317
Lead sponsor
Digital Diagnostics, Inc.
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Aug 24, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Audrey Singh Singh
Contact
singh@digitaldiagnostics.com
7633702127

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion